Veralox Therapeutics

VERALOX Therapeutics, LLC is a small molecule drug discovery & development company based in Frederick, Maryland. Our mission is to accelerate the development of first-in-class therapeutics for patients with unmet medical needs. The founders of VERALOX are drug discovery & development experts from Avalon, Human Genome Sciences, and NIH/NCATS with a track record of successful drug development and commercialization. Launched in 2017, the company is developing VLX-1005, a first-in-class therapeutic for the treatment of heparin-induced thrombocytopenia and thrombosis (HIT/T) and other immune-mediated rare blood disorders.